[Translation] A randomized, double-blind, placebo-controlled, single-center Phase I clinical study to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of a single dose of HST101 in healthy Chinese study participants with mildly elevated low-density lipoprotein cholesterol
"主要目的:
本研究的主要目的是评估HST101单次皮下(SC)给药在中国高胆固醇水平的健康成人研究参与者中的安全性和耐受性。
次要目的:
? 评估HST101单次SC给药后的药代动力学(PK)和剂量比例关系;
? 评估HST101单次SC给药对血清未结合(游离)前蛋白转化酶枯草溶菌素 9(PCSK9)浓度和血清LDL-C浓度的药效学(PD)影响;
? 评估HST101单次SC给药对血脂,包括总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、极低密度脂蛋白胆固醇(VLDL-C)和甘油三酯(TG)的影响;
? 评估HST101单次SC给药对血清载脂蛋白B(Apo B)、Apo A1和脂蛋白(a)[Lp(a)]浓度的影响;
? 评估HST101单次SC给药的PK-PD关系;
? 评估HST101单次SC给药后的免疫原性[抗药抗体(ADAs)/中和抗体(NAbs)]的发生率、滴度及存续时间。"
[Translation] "Primary Objectives:
The primary objective of this study is to evaluate the safety and tolerability of a single subcutaneous (SC) administration of HST101 in healthy adult study participants with high cholesterol levels in China.
Secondary Objectives:
? To evaluate the pharmacokinetic (PK) and dose proportionality relationship of HST101 after a single SC administration;
? To evaluate the pharmacodynamic (PD) effect of a single SC administration of HST101 on serum unbound (free) proprotein convertase subtilisin/kexin type 9 (PCSK9) concentration and serum LDL-C concentration;
? To evaluate the effect of a single SC administration of HST101 on blood lipids, including total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), very low-density lipoprotein cholesterol (VLDL-C), and triglycerides (TG);
? To evaluate the effect of a single SC administration of HST101 on serum apolipoprotein B (Apo B), Apo A1, and lipoprotein (a) [Lp(a)] concentrations;
? To evaluate the PK-PD relationship of a single SC administration of HST101;
? To evaluate the incidence, titer, and duration of immunogenicity [anti-drug antibodies (ADAs)/neutralizing antibodies (NAbs)] of HST101 after a single SC administration.